Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Foxp1 Is Indispensable for Ductal Morphogenesis and Controls the Exit of Mammary Stem Cells from Quiescence.

Fu NY, Pal B, Chen Y, Jackling FC, Milevskiy M, Vaillant F, Capaldo BD, Guo F, Liu KH, Rios AC, Lim N, Kueh AJ, Virshup DM, Herold MJ, Tucker HO, Smyth GK, Lindeman GJ, Visvader JE.

Dev Cell. 2018 Dec 3;47(5):629-644.e8. doi: 10.1016/j.devcel.2018.10.001. Epub 2018 Oct 25.

PMID:
30523786
2.

A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2-positive metastatic breast cancer.

Lindeman GJ, Lok SW, Whittle JR, Vaillant F, Teh CE, Lo LL, Policheni AN, Bergin ART, Desai J, Ftouni S, Gandolfo LC, Liew D, Liu HK, Mann GB, Moodie K, Murugasu A, Pal B, Roberts AW, Rosenthal MA, Shackleton K, Silva MJ, Siow ZR, Smyth GK, Taylor L, Travers A, Yeo B, Yeung MM, Zivanovic Bujak A, Dawson SJ, Gray DHD, Visvader JE.

Cancer Discov. 2018 Dec 5. pii: CD-18-1151. doi: 10.1158/2159-8290.CD-18-1151. [Epub ahead of print]

PMID:
30518523
3.

Canonical PRC2 function is essential for mammary gland development and affects chromatin compaction in mammary organoids.

Michalak EM, Milevskiy MJG, Joyce RM, Dekkers JF, Jamieson PR, Pal B, Dawson CA, Hu Y, Orkin SH, Alexander WS, Lindeman GJ, Smyth GK, Visvader JE.

PLoS Biol. 2018 Aug 6;16(8):e2004986. doi: 10.1371/journal.pbio.2004986. eCollection 2018 Aug.

4.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MGEM, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden ATJM, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Mar 20;118(6):e17. doi: 10.1038/bjc.2018.11. Epub 2018 Mar 6.

5.

Spotlight on the utility of the Oncotype DX® breast cancer assay.

Siow ZR, De Boer RH, Lindeman GJ, Mann GB.

Int J Womens Health. 2018 Feb 21;10:89-100. doi: 10.2147/IJWH.S124520. eCollection 2018. Review.

6.

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.

Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4. Erratum in: Br J Cancer. 2018 Mar 06;:.

7.

Construction of developmental lineage relationships in the mouse mammary gland by single-cell RNA profiling.

Pal B, Chen Y, Vaillant F, Jamieson P, Gordon L, Rios AC, Wilcox S, Fu N, Liu KH, Jackling FC, Davis MJ, Lindeman GJ, Smyth GK, Visvader JE.

Nat Commun. 2017 Nov 20;8(1):1627. doi: 10.1038/s41467-017-01560-x.

8.

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.

Merino D, Whittle JR, Vaillant F, Serrano A, Gong JN, Giner G, Maragno AL, Chanrion M, Schneider E, Pal B, Li X, Dewson G, Gräsel J, Liu K, Lalaoui N, Segal D, Herold MJ, Huang DCS, Smyth GK, Geneste O, Lessene G, Visvader JE, Lindeman GJ.

Sci Transl Med. 2017 Aug 2;9(401). pii: eaam7049. doi: 10.1126/scitranslmed.aam7049.

PMID:
28768804
9.

Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.

Liede A, Mansfield CA, Metcalfe KA, Price MA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG.

Breast Cancer Res Treat. 2017 Sep;165(2):433-444. doi: 10.1007/s10549-017-4332-3. Epub 2017 Jun 17.

10.

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.

Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, Dushyanthen S, Mansour M, Pang JB, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Perou CM, Visvader JE, Gray DHD, Loi S, Lindeman GJ.

Sci Transl Med. 2017 Jun 7;9(393). pii: eaal4922. doi: 10.1126/scitranslmed.aal4922.

11.

RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.

Nolan E, Vaillant F, Visvader JE, Lindeman GJ.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx038. No abstract available.

PMID:
28383640
12.

Identification of quiescent and spatially restricted mammary stem cells that are hormone responsive.

Fu NY, Rios AC, Pal B, Law CW, Jamieson P, Liu R, Vaillant F, Jackling F, Liu KH, Smyth GK, Lindeman GJ, Ritchie ME, Visvader JE.

Nat Cell Biol. 2017 Mar;19(3):164-176. doi: 10.1038/ncb3471. Epub 2017 Feb 13.

PMID:
28192422
13.

Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.

Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, Hamilton A, Ananda S, Lindeman GJ, Scott CL.

Gynecol Oncol. 2017 Apr;145(1):130-136. doi: 10.1016/j.ygyno.2017.01.030. Epub 2017 Feb 3.

PMID:
28162234
14.

Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history.

Skandarajah AR, Thomas S, Shackleton K, Chin-Lenn L, Lindeman GJ, Mann GB.

Breast. 2017 Apr;32:93-97. doi: 10.1016/j.breast.2017.01.002. Epub 2017 Jan 18.

PMID:
28107734
15.

Out-RANKing BRCA1 in Mutation Carriers.

Nolan E, Lindeman GJ, Visvader JE.

Cancer Res. 2017 Feb 1;77(3):595-600. doi: 10.1158/0008-5472.CAN-16-2025. Epub 2017 Jan 19. Review.

16.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

17.

New Monoclonal Antibodies to Defined Cell Surface Proteins on Human Pluripotent Stem Cells.

O'Brien CM, Chy HS, Zhou Q, Blumenfeld S, Lambshead JW, Liu X, Kie J, Capaldo BD, Chung TL, Adams TE, Phan T, Bentley JD, McKinstry WJ, Oliva K, McMurrick PJ, Wang YC, Rossello FJ, Lindeman GJ, Chen D, Jarde T, Clark AT, Abud HE, Visvader JE, Nefzger CM, Polo JM, Loring JF, Laslett AL.

Stem Cells. 2017 Mar;35(3):626-640. doi: 10.1002/stem.2558. Epub 2017 Jan 19.

18.

Derivation of a robust mouse mammary organoid system for studying tissue dynamics.

Jamieson PR, Dekkers JF, Rios AC, Fu NY, Lindeman GJ, Visvader JE.

Development. 2017 Mar 15;144(6):1065-1071. doi: 10.1242/dev.145045. Epub 2016 Dec 19.

19.

The complexities and caveats of lineage tracing in the mammary gland.

Rios AC, Fu NY, Cursons J, Lindeman GJ, Visvader JE.

Breast Cancer Res. 2016 Nov 25;18(1):116.

20.

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.

Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Rohrbach K, Huang LY, Soriano R, Smyth GK, Dougall WC, Visvader JE, Lindeman GJ.

Nat Med. 2016 Aug;22(8):933-9. doi: 10.1038/nm.4118. Epub 2016 Jun 20.

PMID:
27322743
21.

Essential role for a novel population of binucleated mammary epithelial cells in lactation.

Rios AC, Fu NY, Jamieson PR, Pal B, Whitehead L, Nicholas KR, Lindeman GJ, Visvader JE.

Nat Commun. 2016 Apr 22;7:11400. doi: 10.1038/ncomms11400.

22.

Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.

Merino D, Lok SW, Visvader JE, Lindeman GJ.

Oncogene. 2016 Apr 14;35(15):1877-87. doi: 10.1038/onc.2015.287. Epub 2015 Aug 10. Review.

PMID:
26257067
23.

Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits.

Pal B, Chen Y, Bert A, Hu Y, Sheridan JM, Beck T, Shi W, Satterley K, Jamieson P, Goodall GJ, Lindeman GJ, Smyth GK, Visvader JE.

Breast Cancer Res. 2015 Jun 18;17:85. doi: 10.1186/s13058-015-0585-0.

24.

A pooled shRNA screen for regulators of primary mammary stem and progenitor cells identifies roles for Asap1 and Prox1.

Sheridan JM, Ritchie ME, Best SA, Jiang K, Beck TJ, Vaillant F, Liu K, Dickins RA, Smyth GK, Lindeman GJ, Visvader JE.

BMC Cancer. 2015 Apr 3;15:221. doi: 10.1186/s12885-015-1187-z.

25.

Solitary pituitary metastasis from HER2-positive breast cancer.

Kam J, Kam J, Mann GB, Phillips C, Wentworth JM, King J, Lindeman GJ.

Asia Pac J Clin Oncol. 2017 Apr;13(2):e181-e184. doi: 10.1111/ajco.12353. Epub 2015 Apr 14.

PMID:
25869477
26.

Patient-derived xenograft models of breast cancer and their predictive power.

Whittle JR, Lewis MT, Lindeman GJ, Visvader JE.

Breast Cancer Res. 2015 Feb 10;17:17. doi: 10.1186/s13058-015-0523-1. Review.

27.

EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival.

Fu NY, Rios AC, Pal B, Soetanto R, Lun AT, Liu K, Beck T, Best SA, Vaillant F, Bouillet P, Strasser A, Preiss T, Smyth GK, Lindeman GJ, Visvader JE.

Nat Cell Biol. 2015 Apr;17(4):365-75. doi: 10.1038/ncb3117. Epub 2015 Mar 2.

PMID:
25730472
28.

Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features.

James PA, Sawyer S, Boyle S, Young MA, Kovalenko S, Doherty R, McKinley J, Alsop K, Beshay V, Harris M, Fox S, Lindeman GJ, Mitchell G.

Fam Cancer. 2015 Jun;14(2):287-95. doi: 10.1007/s10689-015-9785-0.

PMID:
25678442
29.

Pro-apoptotic Bim suppresses breast tumor cell metastasis and is a target gene of SNAI2.

Merino D, Best SA, Asselin-Labat ML, Vaillant F, Pal B, Dickins RA, Anderson RL, Strasser A, Bouillet P, Lindeman GJ, Visvader JE.

Oncogene. 2015 Jul 23;34(30):3926-34. doi: 10.1038/onc.2014.313. Epub 2014 Sep 29.

PMID:
25263453
30.

Breast-cancer risk in families with mutations in PALB2.

Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan S, Aittomäki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A, Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE, Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KB, Yannoukakos D, Concannon P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N, Peterlongo P, Nevanlinna H, King MC, Couch FJ, Southey MC, Winqvist R, Foulkes WD, Tischkowitz M.

N Engl J Med. 2014 Aug 7;371(6):497-506. doi: 10.1056/NEJMoa1400382.

31.

Dual roles for Id4 in the regulation of estrogen signaling in the mammary gland and ovary.

Best SA, Hutt KJ, Fu NY, Vaillant F, Liew SH, Hartley L, Scott CL, Lindeman GJ, Visvader JE.

Development. 2014 Aug;141(16):3159-64. doi: 10.1242/dev.108498. Epub 2014 Jul 18.

32.

Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?

Phillips KA, Lindeman GJ.

Future Oncol. 2014 Mar;10(4):499-502. doi: 10.2217/fon.13.278. No abstract available.

33.

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators, Moss S, Eeles RA.

Eur Urol. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15. Erratum in: Eur Urol. 2015 Jun;67(6):e126.

34.

In situ identification of bipotent stem cells in the mammary gland.

Rios AC, Fu NY, Lindeman GJ, Visvader JE.

Nature. 2014 Feb 20;506(7488):322-7. doi: 10.1038/nature12948. Epub 2014 Jan 26.

PMID:
24463516
35.

The mammary stem cell hierarchy.

Fu N, Lindeman GJ, Visvader JE.

Curr Top Dev Biol. 2014;107:133-60. doi: 10.1016/B978-0-12-416022-4.00005-6. Review.

PMID:
24439805
36.

The Angelina Jolie effect.

James PA, Mitchell G, Bogwitz M, Lindeman GJ.

Med J Aust. 2013 Nov 18;199(10):646. No abstract available.

PMID:
24237080
37.

Distinct nuclear receptor expression in stroma adjacent to breast tumors.

Knower KC, Chand AL, Eriksson N, Takagi K, Miki Y, Sasano H, Visvader JE, Lindeman GJ, Funder JW, Fuller PJ, Simpson ER, Tilley WD, Leedman PJ, Graham J, Muscat GE, Clarke CL, Clyne CD.

Breast Cancer Res Treat. 2013 Nov;142(1):211-23.

PMID:
24122391
38.

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.

Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J.

Breast Cancer Res. 2013;15(5):R88.

39.

Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.

Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ, Mann GB, Visvader JE, Lindeman GJ.

Cancer Cell. 2013 Jul 8;24(1):120-9. doi: 10.1016/j.ccr.2013.06.002.

40.

Tumour morphology predicts PALB2 germline mutation status.

Teo ZL, Provenzano E, Dite GS, Park DJ, Apicella C, Sawyer SD, James PA, Mitchell G, Trainer AH, Lindeman GJ, Shackleton K, Cicciarelli L; kConFab, Buys SS, Andrulis IL, Mulligan AM, Glendon G, John EM, Terry MB, Daly M, Odefrey FA, Nguyen-Dumont T, Giles GG, Dowty JG, Winship I, Goldgar DE, Hopper JL, Southey MC.

Br J Cancer. 2013 Jul 9;109(1):154-63. doi: 10.1038/bjc.2013.295. Epub 2013 Jun 20.

41.

The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia.

Teo ZL, Sawyer SD, James PA, Mitchell G, Trainer AH, Lindeman GJ, Shackleton K, Cicciarelli L, Southey MC.

Fam Cancer. 2013 Dec;12(4):587-95. doi: 10.1007/s10689-013-9620-4.

PMID:
23471749
42.

Global changes in the mammary epigenome are induced by hormonal cues and coordinated by Ezh2.

Pal B, Bouras T, Shi W, Vaillant F, Sheridan JM, Fu N, Breslin K, Jiang K, Ritchie ME, Young M, Lindeman GJ, Smyth GK, Visvader JE.

Cell Rep. 2013 Feb 21;3(2):411-26. doi: 10.1016/j.celrep.2012.12.020. Epub 2013 Jan 31.

43.

A role for common genomic variants in the assessment of familial breast cancer.

Sawyer S, Mitchell G, McKinley J, Chenevix-Trench G, Beesley J, Chen XQ, Bowtell D, Trainer AH, Harris M, Lindeman GJ, James PA.

J Clin Oncol. 2012 Dec 10;30(35):4330-6. doi: 10.1200/JCO.2012.41.7469. Epub 2012 Oct 29.

PMID:
23109704
44.

Cancer stem cells: current status and evolving complexities.

Visvader JE, Lindeman GJ.

Cell Stem Cell. 2012 Jun 14;10(6):717-728. doi: 10.1016/j.stem.2012.05.007. Review.

45.

Isolation of mouse mammary epithelial subpopulations: a comparison of leading methods.

Smalley MJ, Kendrick H, Sheridan JM, Regan JL, Prater MD, Lindeman GJ, Watson CJ, Visvader JE, Stingl J.

J Mammary Gland Biol Neoplasia. 2012 Jun;17(2):91-7. doi: 10.1007/s10911-012-9257-1. Epub 2012 May 30. Review.

PMID:
22644112
46.

Triple-negative breast cancer: making the most of a misnomer.

McCarthy N, Mitchell G, Bilous M, Wilcken N, Lindeman GJ.

Asia Pac J Clin Oncol. 2012 Jun;8(2):145-55. doi: 10.1111/j.1743-7563.2012.01533.x. Review.

PMID:
22524573
47.

Aldehyde dehydrogenase activity is a biomarker of primitive normal human mammary luminal cells.

Eirew P, Kannan N, Knapp DJ, Vaillant F, Emerman JT, Lindeman GJ, Visvader JE, Eaves CJ.

Stem Cells. 2012 Feb;30(2):344-8. doi: 10.1002/stem.1001.

48.

The unmasking of novel unipotent stem cells in the mammary gland.

Visvader JE, Lindeman GJ.

EMBO J. 2011 Nov 8;30(24):4858-9. doi: 10.1038/emboj.2011.415. No abstract available.

49.

Breast conservation versus mastectomy in triple-negative breast cancer: two steps forward, one step back?

Trainer AH, James PA, Mann GB, Lindeman GJ.

J Clin Oncol. 2011 Dec 10;29(35):4722-3; author reply 4723-4. doi: 10.1200/JCO.2011.38.9684. Epub 2011 Oct 31. No abstract available.

PMID:
22042938
50.

Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.

Thompson ER, Boyle SE, Johnson J, Ryland GL, Sawyer S, Choong DY, kConFab, Chenevix-Trench G, Trainer AH, Lindeman GJ, Mitchell G, James PA, Campbell IG.

Hum Mutat. 2012 Jan;33(1):95-9. doi: 10.1002/humu.21625. Epub 2011 Nov 4.

PMID:
21990120

Supplemental Content

Loading ...
Support Center